However, to reach this conclusion, more and larger studies that focus on the expression of PD-L1 in TNBC patients treated or not with neoadjuvant chemotherapy are needed—for instance, PD-L1 is described to be more commonly expressed in primary tumors than metastatic tumors (p = 0.002) (84), although some controversial results have also been published (85). Here, CD274 is linked to metastatic neoplasm.